April 2, 2021 | Targeted Therapies in Oncology

Triplet Therapy Is Active and Safe in MSH mCRC

April 24, 2021

Clinical Articles

The triplet regimen of nivolumab, ipilimumab, and panitumumab has shown antitumor activity and a consistent safety profile in patients with previously treated metastatic colorectal cancer that is microsatellite stable and KRAS, NRAS, and BRAF wild type, according to findings from the phase 2 LCCC1632 study.

Adjuvant Nivolumab Confers 30% Reduction in Disease Recurrence in MIUC

April 22, 2021

Clinical Articles

Findings from a A phase 3 trial evaluating adjuvant nivolumab following surgery versus placebo demonstrated an improvement in median disease-free survival in patients with muscle-invasive urothelial cancer, according to results from the CheckMate 274 trial presented at the 2021 Genitourinary Cancers Symposium.